AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial

AB122 Controls Disease in Half of Solid Tumor Patients in Phase 1 Trial
A potential antibody treatment called AB122 enabled tumor reduction and stable disease in half of patients with ovarian cancer and other types of advanced tumors, according to early results of an Arcus Biosciences Phase 1 trial. The findings from a small number of patients also revealed that AB122 benefits were similar to that of the approved therapies Opdivo (nivolumab) and Keytruda (pembrolizumab). AB122 is a monoclonal antibody that selectively targets a protein receptor called PD-1 in immune T-cells, blocking its binding to PD-L1 and PD-L2 in cancer cells. This binding is used by tumor cells to evade immune attack. According to Arcus, preclinical work has shown that the biological and pharmacological properties of AB122 are similar to those of Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda, which are immune checkpoint inhibitors also targeting PD-1 antibodies. In a press release, Joyson Karakunnel, MD, Arcus’ vice president of clinical development, said the data “represent an important step in confirming these results in patients.” The Phase 1 dose-escalation trial intends to assess the safety, immunogenicity — the ability to trigger an immune response
Subscribe or to access all post and page content.